PMID- 28458353
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20200826
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 40
IP  - 5
DP  - 2017
TI  - The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential 
      Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
PG  - 675-680
LID - 10.1248/bpb.b16-00964 [doi]
AB  - Sodium glucose cotransporter 2 (SGLT2) inhibitors improve hyperglycemia in 
      patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose 
      excretion. In addition to their antihyperglycemic effect, SGLT2 inhibitors also 
      reduce body weight and fat mass in obese and overweight patients with T2DM. 
      However, whether or not SGLT2 inhibitors similarly affect body composition of 
      non-obese patients with T2DM remains unclear. In this study, we investigated the 
      effect of the SGLT2 inhibitor ipragliflozin on body composition in a 
      Goto-Kakizaki (GK) rat model of non-obese T2DM. GK rats were treated with 
      ipragliflozin once daily for 9 weeks, starting at 23 weeks of age. Body 
      composition was then analyzed using dual-energy X-ray absorptiometry. Treatment 
      with ipragliflozin increased urinary glucose excretion, reduced hemoglobin A1c 
      (HbA1c) levels and suppressed body weight gain as the dose increased. Body 
      composition analysis revealed that body fat mass was lower in the 
      ipragliflozin-treated groups than in the control group, while lean body mass and 
      bone mineral contents were comparable between groups. Thus, an SGLT2 inhibitor 
      ipragliflozin was found to promote preferential loss of fat mass in a rat model 
      of non-obese T2DM. Ipragliflozin might also promote preferential loss of fat in 
      non-obese patients with T2DM.
FAU - Takasu, Toshiyuki
AU  - Takasu T
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Hayashizaki, Yuka
AU  - Hayashizaki Y
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Hirosumi, Jiro
AU  - Hirosumi J
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Minoura, Hideaki
AU  - Minoura H
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Amino, Nobuaki
AU  - Amino N
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Kurosaki, Eiji
AU  - Kurosaki E
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
FAU - Takakura, Shoji
AU  - Takakura S
AD  - Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Slc5a2 protein, rat)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 3N2N8OOR7X (ipragliflozin)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adipose Tissue/*drug effects/pathology
MH  - Animals
MH  - Body Composition/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/pathology
MH  - Diet, High-Fat
MH  - Eating/drug effects
MH  - Glucosides/*pharmacology
MH  - Glycosuria/metabolism
MH  - Hypoglycemic Agents/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Wistar
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/*pharmacology
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - anti-diabetic drug
OT  - body composition
OT  - ipragliflozin
OT  - sodium glucose cotransporter 2 (SGLT2) inhibitor
OT  - type 2 diabetes mellitus
EDAT- 2017/05/02 06:00
MHDA- 2018/02/13 06:00
CRDT- 2017/05/02 06:00
PHST- 2017/05/02 06:00 [entrez]
PHST- 2017/05/02 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1248/bpb.b16-00964 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2017;40(5):675-680. doi: 10.1248/bpb.b16-00964.